Human Immunodeficiency Virus (Hiv) Therapeutics Market Worth Will Be $15 billion in Sales by 2023

Comments

Transcription

Human Immunodeficiency Virus (Hiv) Therapeutics Market Worth Will Be $15 billion in Sales by 2023
Human Immunodeficiency Virus (Hiv)
Therapeutics Market Worth Will Be $15
billion in Sales by 2023
The global HIV therapeutics market was worth approximately $14 billion in 2013, and it is expected to
rise a total of $15 billion in sales by 2023, at a Compound Annual Growth Rate (CAGR) of 0.9%. These
sales are expected to come predominantly from the US market, as financial austerity measures remain a
primary barrier to the growth of the HIV market in the other countries covered in this report.
The global HIV therapeutics Market & Forecasts to 2023 report provides a comprehensive analysis of the
current state of the market and likely future evolution over the next 5 years. This 461-page report with
174 Tables provides a complete analysis of Human Immunodeficiency Virus (Hiv) Therapeutics Market.
Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Human Immunodeficiency
Virus Market Analysis Report at –
http://www.absolutereports.com/pharmapoint-human-immunodeficiency-virus-hiv-global-drugforecast-and-market-analysis-to-2023-10077324
Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system,
destroying or impairing their function. As the infection progresses, the immune system becomes
increasingly weaker, making the infected person more susceptible to other infections. Since the first
anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major
improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been
headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla
(efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level
of convenience.
Ask for Discount on United Kingdom Trauma Fixation Market Research Report at –
http://www.absolutereports.com/enquiry/request-discount/10077324
+1 408 520 9750
www.absolutereports.com
global HIV marketplace - which, for the purposes of this report, comprises nine major pharmaceutical
markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) - to experience modest growth
during the forecast period. This growth will be driven primarily by the highly anticipated arrivals of novel
integrase inhibitor- (INI-) and protease inhibitor- (PI-) based STRs, which include ViiV Healthcare’s
Triumeq (dolutegravir/abacavir/lamivudine), Gilead’s Quad 2
(elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]), and Gilead’s and Janssen’s
darunavir/cobicistat/emtricitabine/TAF. Nevertheless, looming patent expiries of high-grossing branded
drugs in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with compulsory licensing and
generic erosion in Brazil and China, are expected to curtail market growth.
Request sample PDF of this report at - http://www.absolutereports.com/enquiry/requestsample/10077324
Key Questions Answered in This Report:
- How will the HIV market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil,
China) change from 2013-2023?
- What are the most promising late-stage pipeline drugs in HIV?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one
another, and against existing treatment options?
- What are the unmet needs in HIV treatment management?
- What drivers and barriers will affect HIV therapeutics sales in the 9MM over the forecast period?
About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and
taking visionary decisions based on facts and figures derived from in depth market research. We are one
of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of
data parameters.
Contact–
Mr. Ameya Pingaley
Absolute Reports
+1-408 520 9750
Email – [email protected]
Website: www.absolutereports.com
+1 408 520 9750
www.absolutereports.com

Similar documents

Medtronic plc, Bioventus LLC and Depuy Companies Dominate the UK Orthobiologics Market Report

Medtronic plc, Bioventus LLC and Depuy Companies Dominate the UK Orthobiologics Market Report The orthobiologics market in the UK is expected to be driven by patient demographics, the development of novel product designs, increasing patient awareness, increasing participation in sports related activities, and a rising incidence of road accidents. The data in the report is derived from dynamic market forecast models.

More information

First Electric Cooperative Corporation, Update 2015

First Electric Cooperative Corporation, Update 2015 The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services.

More information

France Orthopedic Prosthetics Procedure report to 2021, Market Shares, Research Report, Industry Analysis, Forecast Opportunity

France Orthopedic Prosthetics Procedure report to 2021, Market Shares, Research Report, Industry Analysis, Forecast Opportunity prosthesis is a functional replacement for an amputated or congenitally malformed or missing limb. Prosthetists are responsible for the prescription, design and management of a prosthetic device. In most cases, the prosthetist begins by taking a plaster cast of the patient's affected limb. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market segments - Lower Extremity Prosthetics and Upper Extremity Prosthetics.

More information

Ventricular Fibrillation: Global Industry Analysis, Trends, Market Demands, Segment and Forecast

Ventricular Fibrillation: Global Industry Analysis, Trends, Market Demands, Segment and Forecast Ventricular Fibrillation- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India.

More information

Latest Research Report on Medical Equipment Monthly Deals Analysis: JANUARY 2016 - M&A and Investment Trends

Latest Research Report on Medical Equipment Monthly Deals Analysis: JANUARY 2016 - M&A and Investment Trends Medical Equipment Monthly Deals Analysis: JANUARY 2016 report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in January 2016.

More information

Latest Report: Glioblastoma Treatment Market Will Expand Fivefold to $3.3 Billion at a CAGR of 17.4% by 2024

Latest Report: Glioblastoma Treatment Market Will Expand Fivefold to $3.3 Billion at a CAGR of 17.4% by 2024 The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, representing a rapid Compound Annual Growth Rate (CAGR) of 17.4% according to a leading research and consulting firm. Of the 7MM, Japan will see the most impressive relative growth, with sales expanding from $47 million in 2014 to $268 million in 2024, representing a CAGR of 19.7%.

More information

Hepatitis B Virus (HBV) Therapeutics Market to Expand at a modest Compound Annual Growth Rate (CAGR) of 2.4% Up to 2024

Hepatitis B Virus (HBV) Therapeutics Market to Expand at a modest Compound Annual Growth Rate (CAGR) of 2.4% Up to 2024 The global hepatitis B market, which is set to experience limited growth from $2.4 billion in 2014 to $3 billion by 2024, is being stymied by the persistence of low diagnosis and treatment rates, according to research. Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition.

More information

Hodgkin Lymphoma Market 10 Year Epidemiology Forecasts in 7 Major Markets

Hodgkin Lymphoma Market 10 Year Epidemiology Forecasts in 7 Major Markets The Hodgkin’s lymphoma treatment market is set to increase more than fourfold from $316 million in 2014 to $1.4 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 16%. Hodgkin’s lymphoma (HL), or Hodgkin’s disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12% of all lymphomas and 0.6% of all new cancer cases, but overall prognosis is very good.

More information